Caris Life Sciences,?Inc. (CAI) closed the last trading session at $28.86, gaining 12.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $38.33 indicates a 32.8% upside potential.The average comprises nine short-term price targets ranging from a low of $28.00 to a high of $45.00, with a standard deviation of $4.72. While the lowest estimate indicates a decline of 3% from the curren ...

Core Viewpoint - Enliven Therapeutics, Inc. (ELVN) has seen an 8.2% increase in share price over the past four weeks, closing at $20.56, with a potential upside of 101.3% based on Wall Street analysts' mean price target of $41.38 [1][12]. Price Targets - The average price target consists of eight estimates ranging from a low of $33.00 to a high of $52.00, with a standard deviation of $6.52, indicating a potential increase of 60.5% to 152.9% from the current price [2][9]. - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [2][9]. Analyst Sentiment - Analysts are optimistic about ELVN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has increased by 9% over the past month, with two estimates revised upward and no negative revisions [12]. Zacks Rank - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which further supports the stock's potential upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of ELVN's potential gains, it does provide a useful guide for the direction of price movement [14].

Core Viewpoint - Gen Digital (GEN) shares have shown no gain over the past four weeks, closing at $26.37, but analysts suggest a potential upside of 30.4% based on a mean price target of $34.38 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $5.5, indicating variability among analysts; the lowest estimate suggests a 10% increase to $29.00, while the highest predicts a 74.4% surge to $46.00 [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about GEN's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 1.2%, with one estimate increasing and no negative revisions [12] Zacks Rank and Investment Potential - GEN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Group 1 - Natural Gas Services (NGS) shares have increased by 11.2% over the past four weeks, closing at $30.97, with a mean price target of $39.5 indicating a potential upside of 27.5% [1] - The average price targets range from a low of $34.00 to a high of $45.00, with a standard deviation of $4.51, suggesting a relatively high agreement among analysts regarding the stock's future price movement [2][9] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases, as indicated by a 9.5% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - NGS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets are often viewed as important, they should be approached with skepticism, as they may not reliably predict actual stock price movements [3][10]

Core Viewpoint - Snap (SNAP) shares have shown a slight increase of 0.1% over the past four weeks, closing at $7.61, with analysts suggesting a potential upside of 30.8% based on a mean price target of $9.95 [1] Price Targets and Estimates - The average price target consists of 33 short-term estimates, ranging from a low of $7.00 to a high of $16.00, with a standard deviation of $1.92, indicating variability among analysts [2] - The lowest estimate suggests an 8% decline from the current price, while the highest indicates a potential upside of 110.3% [2] - A low standard deviation signifies greater agreement among analysts regarding price movement, which can be a useful starting point for further research [9] Analyst Sentiment and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher for Snap, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 16.2%, with seven estimates moving higher and no negative revisions [12] - Snap holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set unbiased targets has been questioned [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism to avoid disappointing returns on investment [10]

Core Viewpoint - Paysign, Inc. (PAYS) shows potential for significant upside, with a mean price target of $9.1 indicating a 74% increase from its current price of $5.23 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $0.65, suggesting a consensus among analysts [2] - The lowest estimate of $8.50 indicates a 62.5% increase, while the highest target of $10.00 suggests a 91.2% increase from the current price [2] - Analysts' price targets can be misleading, as they may not accurately reflect the stock's future price movements [3][7] Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding PAYS's ability to report better earnings, which supports the potential for stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.9%, with one estimate moving higher and no negative revisions [12] - PAYS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Amicus Therapeutics (FOLD) has shown a significant price increase of 11.4% over the past four weeks, with a mean price target of $15.64 indicating a potential upside of 58.5% from the current price of $9.87 [1] Price Targets and Analyst Consensus - The average price target consists of 11 estimates ranging from a low of $11.00 to a high of $21.00, with a standard deviation of $3.29, suggesting variability in analyst predictions [2] - The lowest estimate indicates an 11.5% increase, while the highest suggests an upside of 112.8% [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding FOLD's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, three estimates have increased, leading to a Zacks Consensus Estimate rise of 263.6% [12] - FOLD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][10] - Analysts often set optimistic price targets due to business incentives, which can lead to inflated estimates [8]

Core Viewpoint - Shares of Compass Therapeutics, Inc. (CMPX) have increased by 22.2% in the past four weeks, closing at $5.01, with a mean price target of $12.73 indicating a potential upside of 154.1% [1] Price Targets and Analyst Consensus - The average of 11 short-term price targets ranges from a low of $7.00 to a high of $30.00, with a standard deviation of $7.4, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 39.7% increase from the current price, while the highest suggests a 498.8% upside [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Potential Upside - Analysts have shown increasing optimism about CMPX's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 18.7% over the past month, with seven estimates increasing and no negative revisions [12] - CMPX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them may not be prudent due to the questionable ability of analysts to set accurate targets [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8] - Despite the skepticism surrounding price targets, the direction they imply can serve as a useful guide for further research [10][14]

Core Viewpoint - XP Inc. (XP) shows potential for significant upside, with a mean price target of $23.48 indicating a 32.2% increase from its current price of $17.76 [1] Price Targets and Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $3.41, suggesting variability in analyst predictions [2] - The lowest estimate is $18.30, indicating a 3% increase, while the highest estimate is $30.00, suggesting a potential surge of 68.9% [2] - Analysts' price targets should be approached with caution, as they may not reliably indicate future stock prices [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about XP's earnings, with a consensus indicating better-than-previously estimated earnings [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 0.4% rise in the Zacks Consensus Estimate [12] - XP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Implications of Price Targets - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a useful starting point for further research [10][14]

Core Viewpoint - Stagwell (STGW) shares have increased by 4.5% recently, with analysts suggesting a potential upside of 54.5% based on a mean price target of $8.25 [1][11]. Price Targets - The average price target from seven analysts ranges from a low of $6.50 to a high of $10.00, indicating a standard deviation of $1.18, which reflects the variability of estimates [2]. - The lowest estimate suggests a 21.7% increase from the current price, while the highest estimate indicates an 87.3% upside [2]. Analyst Consensus and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11]. - Over the past 30 days, one estimate has increased, leading to a 4.8% rise in the Zacks Consensus Estimate for the current year [12]. Zacks Rank - STGW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13]. Caution on Price Targets - While price targets are a common metric, they can often mislead investors, and reliance solely on them for investment decisions may not be prudent [3][7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].